Dengue Vaccines: An Update

• Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy Vol. 36; no. 3; pp. 325 - 336
• Main Authors: Torres-Flores, Jesús M., Reyes-Sandoval, Arturo, Salazar, Ma Isabel
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-05-2022; Springer Nature B.V
• Subjects: Antibodies; Biomedical and Life Sciences; Biomedicine; Cancer Research; Clinical trials; Dengue fever; Genes; Immunization; Immunogenicity; Infectious diseases; Leading; Leading Article; Medical research; Molecular Medicine; Mosquitoes; Mutation; Pediatrics; Pharmacotherapy; Tropical diseases; Vaccine development; Vaccine efficacy; Vaccines; Vector-borne diseases; Viruses; Thailand
• ISSN: 1173-8804; 1179-190X
• DOI: 10.1007/s40259-022-00531-z

Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term studies to evaluate vaccine efficacy and safety to rule out the risk of vaccine-induced DHS/DSS, particularly in children. At least seven DENV vaccines have undergone different phases of clinical trials; however, only three of them (Dengvaxia
®
, TV003, and TAK-003) have showed promising results, and are addressed in detail in this review in terms of their molecular design, efficacy, and immunogenicity. Safety-related challenges during DENV vaccine development are also discussed.